"FDA grants fast track to SOTIO, LigaChem's soft tissue sarcoma drug"
#medsky #healthcare #hospice #healthpolicy #homehealth
#medsky #healthcare #hospice #healthpolicy #homehealth
FDA grants fast track to SOTIO, LigaChem's soft tissue sarcoma drug
The U.S. FDA has granted fast track designation to SOT106, an experimental drug from SOTIO Biotech and Korea's LigaChem Biosciences, for soft tissue sarcoma, a rare group of connective-tissue tumors that are difficult to treat once they spread or recur.SOT106 is an antibody-drug conjugate (ADC), whi
www.koreabiomed.com
August 27, 2026 at 12:00 PM
"FDA grants fast track to SOTIO, LigaChem's soft tissue sarcoma drug"
#medsky #healthcare #hospice #healthpolicy #homehealth
#medsky #healthcare #hospice #healthpolicy #homehealth
🔴 #$NXTC — Clinical Milestone
NextCure Opts Out of Cost-Sharing for LNCB74 Under LigaChem Collaboration
NextCure informed collaboration partner LigaChem Biosciences that it has opted out of continued cost-sharing for LNCB74, the B7-H4-targeting ADC jointly deve…
https://biostock.app/symbols/NXTC
NextCure Opts Out of Cost-Sharing for LNCB74 Under LigaChem Collaboration
NextCure informed collaboration partner LigaChem Biosciences that it has opted out of continued cost-sharing for LNCB74, the B7-H4-targeting ADC jointly deve…
https://biostock.app/symbols/NXTC
July 14, 2026 at 11:08 AM
🔴 #$NXTC — Clinical Milestone
NextCure Opts Out of Cost-Sharing for LNCB74 Under LigaChem Collaboration
NextCure informed collaboration partner LigaChem Biosciences that it has opted out of continued cost-sharing for LNCB74, the B7-H4-targeting ADC jointly deve…
https://biostock.app/symbols/NXTC
NextCure Opts Out of Cost-Sharing for LNCB74 Under LigaChem Collaboration
NextCure informed collaboration partner LigaChem Biosciences that it has opted out of continued cost-sharing for LNCB74, the B7-H4-targeting ADC jointly deve…
https://biostock.app/symbols/NXTC
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in…
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in…
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers.
findsuperdeals.shop
May 30, 2025 at 4:00 AM
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in…
NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in…
Samsung Biologics expanded its partnership with LigaChem Biosciences to collaborate on projects to develop antibody-drug conjugates (ADC) for cancer treatments, the drugmaker said on Thursday.
January 9, 2025 at 5:26 AM
Samsung Biologics expanded its partnership with LigaChem Biosciences to collaborate on projects to develop antibody-drug conjugates (ADC) for cancer treatments, the drugmaker said on Thursday.
WuXi XDC and LigaChem Optimize ADC Development through Expanded Partnership#China#Shanghai#ADC_Development#WuXi_XDC#LigaChem
WuXi XDC and LigaChem Optimize ADC Development through Expanded Partnership
WuXi XDC and LigaChem Biosciences have enhanced their collaboration with a new MOU to accelerate the development of next-gen ADC therapies, improving treatment options for cancer patients.
third-news.com
February 25, 2025 at 10:42 AM
WuXi XDC and LigaChem Optimize ADC Development through Expanded Partnership#China#Shanghai#ADC_Development#WuXi_XDC#LigaChem
DAAN Biotherapeutics Partners with LigaChem for Advanced ADC Development#South_Korea#Seoul#LigaChem_Biosciences#ADC_Development#DAAN_Biotherapeutics
DAAN Biotherapeutics Partners with LigaChem for Advanced ADC Development
DAAN Biotherapeutics has signed an exclusive licensing agreement with LigaChem Biosciences to enhance antibody-drug conjugate (ADC) therapeutic development.
third-news.com
February 13, 2025 at 5:48 AM
DAAN Biotherapeutics Partners with LigaChem for Advanced ADC Development#South_Korea#Seoul#LigaChem_Biosciences#ADC_Development#DAAN_Biotherapeutics
Samsung Biologics Enhances ADC Development with LigaChem Biosciences Collaboration#South_Korea#Samsung_Biologics#Incheon#LigaChem_Biosciences#ADC_Development
Samsung Biologics Enhances ADC Development with LigaChem Biosciences Collaboration
Samsung Biologics announces the extension of its collaboration with LigaChem Biosciences to enhance antibody-drug conjugate (ADC) development services.
third-news.com
January 9, 2025 at 1:01 AM
Samsung Biologics Enhances ADC Development with LigaChem Biosciences Collaboration#South_Korea#Samsung_Biologics#Incheon#LigaChem_Biosciences#ADC_Development
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
www.viv-media.com/infozx-35617...
www.viv-media.com/infozx-35617...
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
www.viv-media.com
January 9, 2025 at 2:01 PM
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
www.viv-media.com/infozx-35617...
www.viv-media.com/infozx-35617...
